Statera Biopharma, Inc.
STABDelisted Mar 3, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001318641
Statera Biopharma, Inc. was delisted on Mar 3, 2023; its insiders filed their last Form 4 on Oct 28, 2021; 29 institutions reported holding it in 13F filings for Q4 2022, worth $197.5K in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 29
- Q4 2022, −4 vs. previous quarter
- 13F value
- $197.5K
- Reported value at the end of Q4 2022
- Superinvestors holding
- 0
- At the end of Q4 2022
Superinvestors holding STAB, Q4 2022
No superinvestor reported holding STAB at the end of Q4 2022.
Latest insider trades
Open-market purchases and sales by Statera Biopharma, Inc. insiders from Form 4, newest first.
No open-market purchases or sales by Statera Biopharma, Inc. insiders are on file.
Top 10 13F holders, Q4 2022
The largest institutional positions in Statera Biopharma, Inc. at the end of Q4 2022; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 722,390 | $59.0K | 0.00% | −634,556−46.8% | Reduced |
| Acadian Asset Management LLC | 434,862 | $34.0K | 0.00% | +434,862 | New |
| Vanguard Group Inc | 378,677 | $30.7K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 171,110 | $13.9K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 130,774 | $10.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 109,531 | $8.89K | 0.00% | −2,220−2.0% | Reduced |
| Two Sigma Securities, LLC | 81,303 | $6.60K | 0.00% | −17,335−17.6% | Reduced |
| State Street Corp | 68,247 | $5.54K | 0.00% | 00.0% | Unchanged |
| Cambridge Investment Research Advisors, Inc. | 59,825 | $5.00K | 0.00% | −9,000−13.1% | Reduced |
| Price T Rowe Associates Inc | 61,200 | $5.00K | 0.00% | 00.0% | Unchanged |